FFRangio-guided treatment yielded comparable 2-year outcomes to wire-based FFR, though acute presentation increased major adverse cardiac event risk during revascularization (P<0.001).
Observational
Sí
Does FFRangio-guided treatment result in different 2-year major adverse cardiac event rates in patients with acute versus chronic coronary syndromes?
FFRangio-guided treatment yields comparable 2-year outcomes for both ACS and CCS patients, demonstrating its clinical utility across the spectrum of coronary artery disease excluding STEMI.
valor p: p=<0.001
BACKGROUND: The use of angiogram-based fractional flow reserve technologies in routine clinical practice is increasing steadily. Available data suggest that it is associated with comparable clinical outcomes compared with wire-based fractional flow reserve (FFR), but evidence is still limited, especially in patients with acute coronary syndromes (ACSs). The aim of this study was to examine the real-world clinical outcomes of an angiogram based fractional flow reserve technology (FFRangio; CathWorks, Kfar-Saba, Israel) to guide treatment for coronary artery disease in patients presenting with acute versus chronic coronary syndromes (CCSs). METHODS: This is a retrospective, observational study. Our cohort included consecutive patients undergoing coronary angiography in 7 centers (Japan, 6; Israel, 1), whose treatment was guided by FFRangio between January 2021 and December 2023. The primary end point was 2-year cumulative incidence of major adverse cardiac events, stratified by presentation (ACS/CCS) and treatment strategy (revascularization/deferral). RESULTS: <0.001). CONCLUSIONS: In a real-world setting, FFRangio-guided treatment yields 2-year outcomes comparable with current data for wire-based fractional flow reserve for both patients with ACS and patients with CCS. ACS presentation is associated with increased risk for major adverse cardiac events in patients undergoing FFRangio-guided revascularization but not deferral. These results demonstrate the clinical utility of FFRangio-guided treatment across the spectrum of coronary artery disease presentation excluding ST-segment-elevation myocardial infarction. REGISTRATION: URL: https://clinicaltrials.gov/study/NCT05648396?term=FFRangio%20 Unique Identifier: NCT05648396.
Witberg et al. (Wed,) conducted a observational in Coronary artery disease (acute and chronic coronary syndromes). FFRangio-guided treatment vs. Chronic coronary syndromes / Deferral was evaluated on 2-year cumulative incidence of major adverse cardiac events (p=<0.001). FFRangio-guided treatment yielded comparable 2-year outcomes to wire-based FFR, though acute presentation increased major adverse cardiac event risk during revascularization (P<0.001).